

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Larry D. Ward, et al.                           **Examiner:** Unassigned  
**Serial No.:** 10/575,928   **Art Unit:** 1614  
**Filed:** March 22, 2007   **Docket:** 19746  
**For:** POXVIRUS VECTOR ENCODING                           **Dated:** February 12, 2008  
  RETROVIRUS (EG HIV) AND CYTOKINE

**Confirmation No.:** 7073

Commissioner for Patents  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:


In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

---

**CERTIFICATE OF ELECTRONIC FILING**

I hereby certify that this correspondence is being deposited with the United States Patent & Trademark Office via Electronic Filing through the United States Patent and Trademark Office e-business website.

Dated: February 12, 2008

  
Xiaochun Zhu

1. Dale C. J. et al., "Induction of HIV-1 specific T -helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-gamma", *J. Med Primatol* 29: 240-247 (2000) XP009004910;
2. Cao H. et al., "Immunogenicity of a Recombinant Human Immunodeficiency Virus (HIV)-Canarypox Vaccine in HIV-Seronegative Ugandan Volunteers: Results of the HIV Network for Prevention Trials 007 Vaccine Study", *Journal of Infectious Diseases* 187(6): 887-895 (2003) XP002457141;
3. Kim J. J. et al., "In Vivo Engineering of a Cellular Immune Response by Coadministration of IL-12 Expression Vector with a DNA Immunogen", *The Journal of Immunology* 158: 816-826 (1997) XP002103878; and
4. Emery S. et al., "Randomized, Placebo-Controlled, Phase I/IIa Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon- $\gamma$  in HIV-1 Infected Subjects", *Human Vaccines* 1(6): 232-238 (2005) XP002457142.

Reference numbers 1-4 were cited in a Supplementary European Search Report dated November 12, 2007 received from the European Patent Office. Applicants are submitting copies of the above-cited references required by 37 C.F.R. §§1.198 (a)(2)(i) and (ii), together with a copy of the Supplementary Search Report. The relevance of the above-identified references has been described in the Supplementary Search Report. It is further submitted that the reference for Kent S. J. et al., "A Recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogen in macaques", *Vaccine* 18: 2250-2256 (2000), XP004191009 was previously cited in Applicants' Information Disclosure Statement filed on October 24, 2006.

Consideration of this Information Disclosure Statement is respectfully requested, since the art provided may be material to the examination of the present application as defined under 37 C.F.R. §1.56.

Further, the undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,



Xiaochun Zhu  
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343  
XZ:ab